Switching from aromatase inhibitor therapy to camizestrant combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) significantly delayed deterioration in global health status and pain among patients with hormone receptor–positive, human…
SERENA-6 PROs: Switching to Camizestrant Improves QoL in HR+/HER2− Advanced Breast Cancer
